Welcome to our dedicated page for SureNano Science news (Ticker: SURNF), a resource for investors and traders seeking the latest updates and insights on SureNano Science stock.
SureNano Science Ltd. (CSE: SURE, OTCQB: SURNF) is a specialty chemicals company focused on the sale and distribution of its SureNano™ surfactant, a ready-to-mix food grade compound used as a base for high performance nanoemulsions. The company’s news flow provides insight into how it finances and develops this surfactant-focused business and how it pursues opportunities within its licensed territories in Canada and select U.S. states.
News releases from SureNano commonly cover capital raising activities, such as non-brokered private placements of units consisting of common shares and common share purchase warrants, as well as recapitalization steps that include debt settlements with insiders. These announcements often explain intended uses of proceeds, including operating expenses, legal and audit fees, general working capital, and efforts to explore new markets for the SureNano™ surfactant.
Investors and observers can also find updates on equity incentives and corporate governance, including grants of stock options under the company’s incentive stock option plan and the results of shareholder meetings where directors, auditors, and long-term incentive plans are approved. In addition, SureNano’s news has described potential strategic transactions, such as a non-binding letter of intent with GlucaPharm Inc. related to a proposed share exchange transaction involving rights to develop a GLP-1 pharmaceutical compound.
This news page aggregates these disclosures so readers can follow developments in SureNano’s financing plans, licensing-driven surfactant business, and potential business combinations. For those tracking SURE or SURNF, the updates offer a view into how the company manages its capital structure, evaluates new opportunities, and communicates forward-looking plans within the framework of Canadian securities regulation.
SureNano Science (OTCQB: SURNF) completed acquisition of GlucaPharm, issuing 8,100,999 common shares plus warrants to purchase 5,000,000 shares. GlucaPharm's GEP44 is a patented second‑generation GLP peptide licensed from Syracuse University with preclinical weight-loss and glucose benefits and reduced GI side effects.
Management appointed Dr. Nihar R. Pandey as Director and CSO, anticipates IND‑enabling FDA study and Phase I in Australia in coming months, and completed a $1.25 million financing with $0.35 warrants to support near‑term development.
SureNano Science Ltd (OTCQB: SURNF) announced a grant of 1,500,000 stock options to various directors, officers and consultants dated December 12, 2025. The options vest immediately, have an exercise price of CAD $0.18 per share and expire 5 years from issuance or earlier under the company's incentive stock option plan.
Following the grant, the company reports the options represent 4.4% of outstanding common shares. The release reiterates forward-looking cautionary language under Canadian securities legislation.
SureNano (OTCQB: SURNF) closed a non-brokered private placement on December 10, 2025 raising $1,250,000 by issuing 10,000,000 Units at $0.125 per Unit. Each Unit includes one common share and one warrant exercisable at $0.35 for 24 months.
The warrants and 600,000 finder’s warrants carry an acceleration provision if the company’s CSE share price trades at $0.50 for 10 consecutive trading days; hold periods expire four months and one day from issuance. The company paid $75,000 in cash commissions. Proceeds are earmarked for operating expenses, legal and audit fees, working capital, market exploration for SureNano surfactant, and evaluating potential business combinations or acquisitions.
SureNano (OTCQB: SURNF) entered a non-binding letter of intent dated November 19, 2025 to pursue a proposed share-exchange acquisition of GlucaPharm, a private BC company that holds rights to Syracuse University’s GEP-44 GLP-1 compound and related IP.
The LOI permits due diligence, mutual exclusivity and sets that GlucaPharm shareholders are expected to own under 20% of SureNano post-closing, subject to a Definitive Agreement, regulatory and third-party approvals and completion of customary due diligence. No guarantee of closing was given.
Separately, SureNano previously announced a private placement up to $1,250,000 (up to 10,000,000 units at $0.125 each) with warrants exercisable at $0.35 for 24 months and an acceleration provision if CSE price exceeds $0.50.
SureNano (OTCQB: SURNF) announced a private placement dated November 5, 2025 to raise up to $1,250,000 by issuing up to 10,000,000 units at $0.125 per Unit.
Each Unit includes one common share and one warrant exercisable at $0.35 for 24 months. Warrants include an acceleration provision if the Company's CSE share price closes at $0.50 or higher for ten consecutive trading days after the four‑month hold period, in which case warrants may expire 30 days after notice. Finders may receive 6% cash and 6% warrants. Proceeds are for operating expenses, legal and audit fees, working capital, market exploration for SureNano surfactant, and investigating complementary industries. All securities are subject to a four‑month and one‑day hold period.
SureNano Science (OTCQB:SURNF) has completed a private placement financing, raising $245,000 through the issuance of 2,450,000 common shares at $0.10 per share. The financing includes $85,000 in debt conversion and $160,000 in cash proceeds.
Company President Charles Malette participated significantly, investing $110,000 in cash and converting $85,000 in debt. Following the transaction, Malette will own 9,621,600 shares, representing 40% ownership of the company. The funds will be used for operating expenses and working capital.
SureNano Science (OTCQB:SURNF) has announced a recapitalization plan consisting of two key components: a $85,000 debt settlement with insider Charles Malette and a private placement to raise up to $215,000. Both transactions will issue shares at $0.10 per share, totaling up to 3,000,000 shares.
The company also reported results from its August 8, 2025 annual general and special meeting, where 70.29% of shareholders participated. All proposed directors were unanimously elected, Buckley Dodds CPA was appointed as auditor, and the long-term incentive plan was approved. Upon completion of the debt settlement, director Charles Malette will own 34.8% of common shares.